Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated With Medium Doses of Inhaled Glucocorticosteroids
Brief Summary: This study is being conducted to demonstrate the non-inferiority between two inhaled glucocorticosteroids and long-acting bronchodilator combination drugs called mometasone furoate/formoterol fumarate in a metered-dose inhaler (MDI) and fluticasone propionate/salmeterol in a dry powder inhaler (DPI) on lung function. Information on the onset of action, the overall safety, and how the drugs control asthma will also be assessed. The study is approximately 1 year in duration.


Options:
A: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID
C: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Intervention Type: DRUG; Name: QVM149 150/50/80 μg o.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6 | Intervention Type: DRUG; Name: QVM149 150/50/160 μg o.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6 | Intervention Type: DRUG; Name: salmeterol/fluticasone FDC 50/500 μg b.i.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6
D: Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 110 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 100/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 250/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 200/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 500/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg | Intervention Type: DRUG; Name: FLOVENT HFA; Assigned to Arm(s): FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg | Intervention Type: DRUG; Name: ADVAIR DISKUS; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg | Intervention Type: DRUG; Name: albuterol/salbutamol HFA; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg, FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg, FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg

Answer: A